Keros Therapeutics Files 8-K
Ticker: KROS · Form: 8-K · Filed: Dec 12, 2024 · CIK: 1664710
| Field | Detail |
|---|---|
| Company | Keros Therapeutics, Inc. (KROS) |
| Form Type | 8-K |
| Filed Date | Dec 12, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: regulatory-filing, sec-filing
TL;DR
Keros Therapeutics filed a routine 8-K on Dec 12, 2024. No major news.
AI Summary
Keros Therapeutics, Inc. filed an 8-K on December 12, 2024, reporting other events and financial statements. The filing does not contain specific details about new material events or financial figures beyond the standard reporting requirements.
Why It Matters
This filing indicates Keros Therapeutics is fulfilling its regulatory reporting obligations with the SEC, which is standard practice for publicly traded companies.
Risk Assessment
Risk Level: low — This is a routine regulatory filing with no new material information disclosed.
Key Players & Entities
- Keros Therapeutics, Inc. (company) — Registrant
- December 12, 2024 (date) — Date of earliest event reported
- 001-39264 (company) — SEC File Number
- 81-1173868 (company) — I.R.S. Employer Identification No.
- Lexington, Massachusetts (location) — Principal executive offices
FAQ
What is the purpose of this 8-K filing?
This 8-K filing serves as a current report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934, indicating the date of the earliest event reported is December 12, 2024.
What are the main items reported in this filing?
The filing is categorized under 'Other Events' and 'Financial Statements and Exhibits'.
What is Keros Therapeutics, Inc.'s principal executive office address?
The principal executive offices are located at 1050 Waltham Street, Suite 302, Lexington, Massachusetts 02421.
What is the SEC file number for Keros Therapeutics, Inc.?
The SEC file number for Keros Therapeutics, Inc. is 001-39264.
When is Keros Therapeutics, Inc.'s fiscal year end?
Keros Therapeutics, Inc.'s fiscal year ends on December 31.
Filing Stats: 483 words · 2 min read · ~2 pages · Grade level 10.2 · Accepted 2024-12-12 06:01:23
Key Financial Figures
- $0.0001 — ge on which registered Common Stock, $0.0001 par value per share KROS The Nasdaq Sto
Filing Documents
- kros-20241212.htm (8-K) — 36KB
- exhibit991121224pr.htm (EX-99.1) — 11KB
- 0001664710-24-000102.txt ( ) — 175KB
- kros-20241212.xsd (EX-101.SCH) — 2KB
- kros-20241212_lab.xml (EX-101.LAB) — 22KB
- kros-20241212_pre.xml (EX-101.PRE) — 13KB
- kros-20241212_htm.xml (XML) — 3KB
01 Other Events
Item 8.01 Other Events. On December 12, 2024, Keros Therapeutics, Inc. (the "Company") announced that it has voluntarily halted dosing in the 3.0 mg/kg and 4.5 mg/kg treatment arms in the ongoing TROPOS trial, a Phase 2 clinical trial of cibotercept (KER-012) in combination with background therapy in patients with pulmonary arterial hypertension, based on a safety review due to the unanticipated observation of pericardial effusion adverse events in the trial. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press release dated December 12 , 2024. 104 Cover Page Interactive Data File (the cover page XBRL tags are embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. KEROS THERAPEUTICS, INC. By: /s/ Jasbir Seehra Jasbir Seehra, Ph.D. Chief Executive Officer Dated: December 12, 2024